source
- Summit Therapeutics cancels $500 million public offering amid weak market conditionsSummit Therapeutics announced it is no longer pursuing a $500 million public offering, citing unfavorable market conditions. The biotech sector has recently seen record‑setting initial public offe…
- Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and fundingNovartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…